400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / Apoptosis / PERK / 1-(5-(4-Amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)indolin-1-yl)-2-(3-fluoro-5-(trifluoromethyl)phenyl)ethan-1-one
CAS No.: 1337531-89-1
Synonyms: 3-Fluoro-GSK2606414;GSK PERK Inhibitor
GSK PERK inhibitor is a biochemical for proteomics research.
生物活性
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT02338622 | Advanced Cancer | Phase 1 | Unknown | October 2015 | United Kingdom ... more >> Northern Institute for Cancer, Freeman Hospital Recruiting Newcastle, Newcastle upon Tyne, United Kingdom, NE7 7DN Contact: Elizabeth R Plummer, MD +44(0)191 213844 ruth.plummer@newcastle.ac.uk Principal Investigator: Elizabeth R Plummer, MD Royal Marsden NHS Foundation Trust Recruiting Sutton, Surrey, United Kingdom, SM2 5PT Contact: Timothy A Yap, PhD 0208 661 3539 timothy.yap@icr.ac.uk Principal Investigator: Timothy A Yap, PhD Collapse << |
NCT02015117 | Metastatic Malignant Neoplasm ... more >>in the Brain Collapse << | Phase 1 | Active, not recruiting | - | United States, Ohio ... more >> Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 Collapse << |
NCT02881242 | Hormone-Resistant Prostate Can... more >>cer Metastatic Prostate Carcinoma Recurrent Prostate Carcinoma Stage IV Prostate Cancer Collapse << | Phase 2 | Recruiting | January 31, 2021 | United States, California ... more >> UCLA / Jonsson Comprehensive Cancer Center Recruiting Los Angeles, California, United States, 90095 Contact: Matthew B. Rettig 310-794-3565 mrettig@mednet.ucla.edu Principal Investigator: Matthew B. Rettig Collapse << |
实验方案
技术信息
CAS号 | 1337531-89-1 | 储存条件 |
|
|
分子式 | C24H19F4N5O | 运输 | 蓝冰 | |
分子量 | 469.43 | 别名 | 3-Fluoro-GSK2606414;GSK PERK Inhibitor |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT02338622 | Advanced Cancer | Phase 1 | Unknown | October 2015 | United Kingdom ... more >> Northern Institute for Cancer, Freeman Hospital Recruiting Newcastle, Newcastle upon Tyne, United Kingdom, NE7 7DN Contact: Elizabeth R Plummer, MD +44(0)191 213844 ruth.plummer@newcastle.ac.uk Principal Investigator: Elizabeth R Plummer, MD Royal Marsden NHS Foundation Trust Recruiting Sutton, Surrey, United Kingdom, SM2 5PT Contact: Timothy A Yap, PhD 0208 661 3539 timothy.yap@icr.ac.uk Principal Investigator: Timothy A Yap, PhD Collapse << |
NCT02015117 | Metastatic Malignant Neoplasm ... more >>in the Brain Collapse << | Phase 1 | Active, not recruiting | - | United States, Ohio ... more >> Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 Collapse << |
NCT02881242 | Hormone-Resistant Prostate Can... more >>cer Metastatic Prostate Carcinoma Recurrent Prostate Carcinoma Stage IV Prostate Cancer Collapse << | Phase 2 | Recruiting | January 31, 2021 | United States, California ... more >> UCLA / Jonsson Comprehensive Cancer Center Recruiting Los Angeles, California, United States, 90095 Contact: Matthew B. Rettig 310-794-3565 mrettig@mednet.ucla.edu Principal Investigator: Matthew B. Rettig Collapse << |
NCT01582997 | Cancer | Phase 1 | Completed | - | Japan ... more >> GSK Investigational Site Shizuoka, Japan, 411-8777 GSK Investigational Site Tokyo, Japan, 104-0045 Collapse << |
NCT01324258 | Solid Tumours | Phase 1 | Completed | - | Japan ... more >> GSK Investigational Site Osaka, Japan, 589-8511 GSK Investigational Site Tokyo, Japan, 181-8611 Collapse << |
NCT00880321 | Cancer | Phase 1 | Completed | - | United States, California ... more >> GSK Investigational Site Los Angeles, California, United States, 90025 United States, New York GSK Investigational Site New York, New York, United States, 10016 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37203 United States, Texas GSK Investigational Site Houston, Texas, United States, 77030 Australia, New South Wales GSK Investigational Site Randwick, New South Wales, Australia, 2031 GSK Investigational Site Westmead, New South Wales, Australia, 2145 Australia, South Australia GSK Investigational Site Adelaide, South Australia, Australia, 5000 Australia, Western Australia GSK Investigational Site Nedlands, Western Australia, Australia, 6009 Collapse << |
NCT02065063 | Cancer | Phase 1 | Completed | - | United States, Massachusetts ... more >> GSK Investigational Site Boston, Massachusetts, United States, 02114 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37232 United States, Texas GSK Investigational Site Houston, Texas, United States, 77030-4009 Collapse << |
NCT03266159 | Solid Tumours | Phase 2 | Withdrawn(Study withdrawn befo... more >>re active to fully evaluate impact of changing practice in target population.) Collapse << | August 19, 2020 | - |
NCT01072175 | Cancer | Phase 2 | Completed | - | United States, California ... more >> Novartis Investigative Site Los Angeles, California, United States, 90025 Novartis Investigative Site San Francisco, California, United States, 94115 United States, Colorado Novartis Investigative Site Aurora, Colorado, United States, 80045 United States, Connecticut Novartis Investigative Site New Haven, Connecticut, United States, 06520 United States, Florida Novartis Investigative Site Tampa, Florida, United States, 33612 United States, Maryland Novartis Investigative Site Lutherville-Timonium, Maryland, United States, 21093 United States, Massachusetts Novartis Investigative Site Boston, Massachusetts, United States, 02114 Novartis Investigative Site Boston, Massachusetts, United States, 02215 United States, Minnesota Novartis Investigative Site Rochester, Minnesota, United States, 55905 United States, Pennsylvania Novartis Investigative Site Philadelphia, Pennsylvania, United States, 19104 United States, Tennessee Novartis Investigative Site Nashville, Tennessee, United States, 37203 Novartis Investigative Site Nashville, Tennessee, United States, 37232 United States, Texas Novartis Investigative Site Houston, Texas, United States, 77030-4009 Australia, New South Wales Novartis Investigative Site Westmead, New South Wales, Australia, 2145 Australia, Victoria Novartis Investigative Site Heidelberg, Victoria, Australia, 3084 Collapse << |
NCT02314143 | Melanoma | Phase 2 | Completed | - | France ... more >> GSK Investigational Site Bordeaux, France, 33075 GSK Investigational Site Marseille cedex 5, France, 13385 GSK Investigational Site Reims Cedex, France, 51092 GSK Investigational Site Rennes Cedex, France, 35042 GSK Investigational Site Villejuif cedex, France, 94805 Spain GSK Investigational Site Barcelona, Spain, 08036 GSK Investigational Site Madrid, Spain, 28041 Collapse << |
NCT01476137 | Cancer | Phase 1 | Completed | - | United States, Texas ... more >> GSK Investigational Site Dallas, Texas, United States, 75246 GSK Investigational Site San Antonio, Texas, United States, 78229 Collapse << |
NCT02281760 | BRAF V600E Mutation | Phase 2 | Completed | - | United States, Maryland ... more >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Collapse << |
NCT01938443 | Cancer | Phase 1 | Completed | - | France ... more >> GSK Investigational Site Villejuif Cedex, France, 94805 United Kingdom GSK Investigational Site London, United Kingdom, W12 0HS GSK Investigational Site London, United Kingdom, W1G 6AD GSK Investigational Site Newcastle upon Tyne, United Kingdom, NE7 7DN Collapse << |
NCT01072175 | - | - | Completed | - | - |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网